REDWOOD CITY, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that data from ongoing clinical trials of two novel anti-cancer stem cell therapeutics, both targeting the Notch cancer stem cell pathway and being evaluated in advanced pancreatic cancer, have been accepted for presentation at the upcoming 2014 Gastrointestinal Cancers Symposium being held January 16-18, 2014 at the Moscone West Convention Center in San Francisco, California.
Help employers find you! Check out all the jobs and post your resume.
